Novartis Pipeline

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.

Download the Novartis pipeline as of December 31, 2022 (PDF 0.1 MB)

Show Filters
Showing 113 results
  • CFZ533
    Sjorgen’s Syndrome (SjS)
    Immunology Phase 2 ≥ 2026 CD40 inhibitor (Blocking, non-depleting, anti-CD40 monoclonal antibody)
    Lead Indication
  • CFZ533
    Lupus Nephritis
    Cardiovascular Phase 2 CD40 inhibitor (Blocking, non-depleting, anti-CD40 monoclonal antibody)
  • CMK389
    Pulmonary sarcoidosis
    Others Phase 2 IL-18 inhibitor
    Lead Indication
  • COA566
    Malaria uncomplicated (<5kg patients)
    Others Phase 3 2024
    Supplementary Indication
  • DFF332
    Renal cell carcinoma
    Oncology: Solid Tumors Phase 1 HIF2A inhibitor
    Lead Indication
  • DFT383
    Cystinosis pre/post kidney transplant
    Neuroscience Phase 1 CTNS gene delivery
    Lead Indication
  • DFV890
    Immunology Phase 2 NLRP3 inhibitor
    Lead Indication
  • DFV890
    Familial cold auto-inflammatory syndrome
    Immunology Phase 2 NLRP3 inhibitor
    New Indication
  • DFV890
    Low risk myelodysplastic syndrome
    Oncology: Hematology Phase 1 ≥ 2026 NLRP3 inhibitor
  • DLX313
    DLX313 (UCB0599)
    Parkinson’s disease
    Neuroscience Phase 2 ≥ 2026 Alpha-synuclein Inhibitor
    Lead Indication
  • EDI048
    Others Phase 1 CpPI(4)K inhibitor
    Lead Indication
  • ETB115
    Radiation sickness syndrome
    Oncology: Hematology Phase 3 2025 Thrombopoietin receptor (TPO-R) Agonist
    Supplementary Indication
  • EXV811
    IgA nephropathy
    Cardiovascular Phase 3 ETₐ receptor antagonist
    Lead Indication
  • EYU688
    Others Phase 1 NS4B inhibitor
    Lead Indication
  • FUB523
    IgA nephropathy
    Cardiovascular Phase 3 Anti-APRIL
    Lead Indication
  • HRO761
    Solid tumors
    Oncology: Solid Tumors Phase 1 Werner inhibitor
    Lead Indication
  • IAG933
    Oncology: Solid Tumors Phase 1
    Lead Indication
  • IGE025
    Food allergy
    Immunology Phase 3 2023 IgE Inhibitor (High-affinity anti-IgE monoclonal antibody)
    Supplementary Indication
  • IGE025
    Immunology Registration IgE Inhibitor (High-affinity anti-IgE monoclonal antibody)
    Supplementary Indication
  • INC424
    Acute GVHD, Pediatrics
    Oncology: Hematology Phase 2 2024 JAK1/2 inhibitor
    Supplementary Indication

Combination abbreviations:
fulv    fulvestrant
tmx    tamoxifen
gsn    goserelin
NSAI  Non-steroidal aromatase inhibitor
Taf     Tafinlar® (dabrafenib)
Mek   Mekinist® (trametinib)

a    EU filing, approved in US.
b    US filing, approved in EU.
c    US filing, submitted in EU.
d    US pending submission, approved in EU
e    EU filing, submitted in US.


This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.